BinaxNOW™ COVID-19 Rapid Antigen Test Kit



Guidance

BACKGROUND

There is increasing evidence that Rapid Point of Care (POC) Testing may be an additional tool in the testing landscape towards reducing the spread of COVID-19. Rapid antigen tests are commonly used in the diagnoses of respiratory pathogens. The FDA has granted emergency use authorization for several antigen tests that can identify SARS-CoV-2 including the BinaxNOW™ antigen test.

BinaxNOW™ antigen tests can detect the presence of the nucleocapsid of SARS-CoV-2 virus and provide results in less than 20 minutes. These tests have been approved as Clinical Laboratory Improvement Amendments (CLIA) of 1988 waived, point-of-care tests. Of note, the performance of rapid antigen tests depends on the circumstances in which they are used. These tests appear to perform best when viral load is highest. Sacramento County Public Health has received an allocation of BinaxNOW™ kits. Settings prioritized to receive a portion of this allocation include jails, schools, community clinics and FQHCs, urgent care clinics and emergency departments, and first responders.

The following guidance should help aid in the use, requesting, distribution, recording/reporting and attestation process.

STEP 1: CLIA WAIVER

- Each recipient needs to apply for a CLIA waiver for use of the antigen test kits.
- If your facility has a CLIA Waiver, you do not need to apply for an additional waiver for the BinaxNOW™ tests.
- If you do not have a waiver, more information can be found here: https://www.cdph.ca.gov/Programs/OSPHLD/LFS/Pages/Guidelines-for-Performing-Waived-Antigen-Testing.aspx

STEP 2: REQUESTING PROCESS AND ATTESTATION

- Requests are to be sent to the <u>Medical Health Operational Area Coordinator (MHOAC)</u> and the established Multi-Agency Coordination (MAC) process.
- All requestors **must** register as a Non-Governmental Entity **and** Health Care Facility, regardless of actual type of organization.
- Requestors must submit a completed Attestation Statement, which must be signed by a
 person designated to represent the health care provider/facility. This Attestation must
 be submitted when submitting a resource request for a supply of BinaxNOW™ antigen
 test kits through the MHOAC.
- Requestors must include a copy of their CLIA waiver with their request.

 Requesting agencies must track the supply of BinaxNOW™ tests they receive and use monthly. If an entity is requesting on behalf of other facilities under their purview, quantities, locations, and utilization must be tracked separately for each facility.

STEP 3: STORAGE

BinaxNOW™ test kits need to be stored in a temperature controlled setting (36°-86°F; 2°-30° C).

STEP 4: RECORDING & REPORTING

To ensure reliable results, it is best to limit the reading and interpretation of the test to a small number of well-trained individuals in a CLIA waived facility. Visit the NAVICA and BinaxNOW™
COVID-19 Ag Card Training Site
to access resources which will guide you on use of the BinaxNOW™ Ag and Navica App reporting tool at your testing location. All test results (positive or negative) must also be reported via the CalREDIE Manual Lab Reporting Module (see attached registration and use instructions).

STEP 5: USE OF KITS & CONFIRMATORY PCR TESTING

Antigen tests tend to have lower sensitivity than the gold standard PCR testing; therefore, these tests yield accurate results when performed on symptomatic individuals within the appropriate window period. BinaxNOW™ antigen tests perform best in symptomatic individuals within 1 week of symptom onset.

- Confirmatory PCR testing is not required for positive antigen result on symptomatic individuals.
- Confirmatory PCR is required for a negative antigen test in someone who has symptoms.
- If confirmatory PCR testing is to be done for any reason, specimen has to be collected within 24 hours of antigen test.

Providers who choose to use BinaxNOW test kits in asymptomatic person are encouraged to use the <u>modified interpretation guidance</u> developed by United in Health based on research in California.

From a clinical perspective, a positive antigen test result in an asymptomatic person *may* be a false positive result. Providers are encouraged to collect another specimen and conduct confirmatory PCR testing in an asymptomatic person with an initial positive antigen test result. The person being tested is required to isolate while awaiting the results of PCR testing.

From a disease reporting perspective, all COVID-19 test results, including antigen test results, must be reported to the local health department. An individual with a positive COVID-19 antigen test only will be counted as a probable case of COVID-19 and will not be included in State or local counts of confirmed cases. However, probable cases receive the same case investigation and contact tracing follow-up by public health personnel as confirmed cases.

Visit the BinaxNOW™ COVID-19 Ag Card Training Site to access resources (NAVICA and BinaxNOW™ COVID-19 Ag Card Training Site), which will guide you on how to successfully employ the BinaxNOW™ Ag Card. The site contains training tools, including videos, to implement patient testing at your site. The site will also guide you on utilizing the free NAVICA app, a mobile app intended to be used with BinaxNOW™ COVID-19 Ag Card. This app will notify patients of their results, whether positive or negative.

ATTACHMENTS


- BinaxNOW™ COVID-19 Antigen Test Kits Recipient Attestation Statement
- COVID-19 Antigen Test Interpretation Algorithm
- CLIA Waiver Application
- CalREDIE Manual Lab Reporting Account Authorization Form
- CalREDIE Manual Lab Reporting Account Quick Start Guide

BinaxNOW™ COVID-19 Rapid Antigen Test Kit



Recipient Attestation Statement

I, the	e undersigned, with i	responsibility for	(name of health care				
prov	ider/facility), attest	to the following:					
✓	The named facility	has a valid Clinical Laboratory Impi	rovement Amendments (CLIA) Certificate of Waiver				
✓	Facility will ensure that personnel responsible for BinaxNOW™ test collection, interpretation of resu and quality control have received the appropriate training, in accordance with manufacturer instruction and the conditions of the CLIA Waiver.						
✓	Facility will, in accordance with the COVID-19 Antigen Test Interpretation algorithm, collect a molecutest (PCR) in addition to the BinaxNOW™ test.						
✓	Facility agrees to record both positive and negative BinaxNOW™ results via the Navica App						
✓	Facility agrees to register for CalREDIE Manual Laboratory Reporting Module and report all BinaxNOW test results (positive or negative).						
✓	Facility will track al	l test cards used (even those waste	d/discarded).				
	Name (Please Print):						
	Signature:		Date:				
	Facility Name:						
	Facility Address:						
	Facility Phone:						



CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA) APPLICATION FOR CERTIFICATION

I. GENERAL INFORMATION						
☐ Initial Application	s	urvey	CLIA IDENTIFICATION NUMBER			
Change in Certificate Typ	e					
Other Changes (Specify)			D			
Effective Date			(If an initial application leave bla	ınk, a number wili i	be assigned)	
Effective Date						
FACILITY NAME			FEDERAL TAX IDENTIFICATION NUMBER			
EMAIL ADDRESS			TELEPHONE NO. (Include area code	FAX NO. (Include	FAX NO. (Include area code)	
FACILITY ADDRESS — Physical Locatic if applicable.) Fee Coupon/Certificate win mailing or corporate address is specified	ll be mailed to this A		MAILING/BILLING ADDRESS (If different from facility address) send Fee Coupon or certificate			
			NUMBER, STREET			
CITY	STATE	ZIP CODE	CITY	STATE	ZIP CODE	
SEND FEE COUPON TO THIS ADDRESS	SEND CERTIFICATE	TO THIS ADDRESS	CORPORATE ADDRESS (If differen	 t from facility) send Fe	ee Coupon or certificate	
Physical	Physical					
Mailing	Mailing		NUMBER, STREET			
☐ Corporate	☐ Corporate					
NAME OF DIRECTOR (Last, First, Midd	le Initial)		CITY	STATE	ZIP CODE	
CREDENTIALS			FOR OFFICE USE ONLY			
			Date Received			
II. TYPE OF CERTIFICATE REC certificate testing requirements		k only one) Plea	se refer to the accompanying	instructions for i	inspection and	
☐ Certificate of Waiver (Co	mplete Sectior	ns I – VI and IX	- X)			
Certificate for Provider Performed Microscopy Procedures (PPM) ((Complete Sections I-VII and IX-X)						
Certificate of Compliance (Complete Sections I – X)						
Certificate of Accreditation (Complete Sections I – X) and indicate which of the following organization(s) your laboratory is accredited by for CLIA purposes, or for which you have applied for accreditation for CLIA purposes.						
☐ The Joint Commiss	ion 🗌 A	AHHS/HFAP	☐ AABB ☐ A2LA			
☐ CAP	□ co	DLA	ASHI			
If you are applying for a Certific	cate of Accredita	ation, you must	provide evidence of accredita	tion for your lab	oratory by an	

If you are applying for a Certificate of Accreditation, you must provide evidence of accreditation for your laboratory by an approved accreditation organization as listed above for CLIA purposes or evidence of application for such accreditation within 11 months after receipt of your Certificate of Registration.

NOTE: Laboratory directors performing non-waived testing (including PPM) must meet specific education, training and experience under subpart M of the CLIA regulations. Proof of these qualifications for the laboratory director must be submitted with this application.

PRA Disclosure Statement

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0581. Expiration Date: 3/31/2021. The time required to complete this information collection is estimated to average one hour per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850. *****CMS Disclaimer*****Please do not send applications, claims, payments, medical records or any documents containing sensitive information to the PRA Reports Clearance Office. Please note that any correspondence not pertaining to the information collection burden approved under the associated OMB control number listed on this form will not be reviewed, forwarded, or retained. If you have questions or concerns regarding where to submit your documents, please contact LabExcellence@cms.hhs.gov.

III.	TYPE OF LA	ABORATORY (Check the one mo	st descriptive of fa	cility type)			
□ 01 Ambulance □ 11 Health Main □ 02 Ambulatory Surgery Center □ 12 Home Healt □ 03 Ancillary Testing Site in □ 13 Hospice □ Health Care Facility □ 14 Hospital □ 04 Assisted Living Facility □ 15 Independen □ 05 Blood Bank □ 16 Industrial □ 06 Community Clinic □ 17 Insurance □ 07 Comp. Outpatient Rehab Facility □ 18 Intermediate □ 08 End Stage Renal Disease □ Individuals voice □ 19 Mobile Labor □ 09 Federally Qualified □ 19 Mobile Labor □ 19 Health Center □ 20 Pharmacy				4 Hospital 5 Independent 6 Industrial 7 Insurance 8 Intermediate C Individuals wit Disabilities 9 Mobile Labora 0 Pharmacy 1 Physician Offic	Agency Care Facilities for h Intellectual tory	☐ 23 ☐ 24 ☐ 25 ☐ 26 S ☐ 27 S N ☐ 28 T ☐ 29 C	Prison Prison Public Health Labo Rural Health Clinic Ichool/Student Heal Ikilled Nursing Fac Jursing Facility Sissue Bank/Reposity Other (Specify)	oratories Ealth Service ility/ tories
IV.	HOURS OF			-				24/7 Check Here
		SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
	FROM:							
	TO:							
(For	multiple sites,	attach the addition	onal information (using the same for	mat.)			
۷. ا	MULTIPLE S	ITES (must meet	one of the regula	tory exceptions to	apply for this p	rovision in 1-3 belo	w)	
Indi 1. 2.	mobile unit providing laboratory testing, health screening fairs, or other temporary testing locations, and may be covered under the certificate of the designated primary site or home base, using its address? Yes No If yes and a mobile unit is providing the laboratory testing, record the vehicle identification number(s) (VINs) and attach to the application.							
NAME AND ADDRESS/LOCATION				TESTS PERFORMI	ED/SPECIALTY/S	UBSPECIALTY		
NAME OF LABORATORY OR HOSPITAL DEPARTMENT								
ADDRESS/LOCATION (Number, Street, Location if applicable)								
CITY, STATE, ZIP CODE TELEPHONE NO. (Include area code)			ode)					
NAME OF LABORATORY OR HOSPITAL DEPARTMENT								
ADD	RESS/LOCATION	(Number, Street, Lo	cation if applicable)					
CITY, STATE, ZIP CODE TELEPHONE NO. (Include area code)			ode)					

In the next three sections, indicate testing performed and annual test volume.
VI. WAIVED TESTING If <u>only</u> applying for a Certificate of Waiver, complete this section and skip sections VII (PPM Testing) and VIII (Non-Waived Testing).
Identify the waived testing (to be) performed. Be as specific as possible. This includes each analyte test system or device used in the laboratory. e.g. (Rapid Strep, Acme Home Glucose Meter)
Indicate the ESTIMATED TOTAL ANNUAL TEST volume for all waived tests performed
☐ Check if no waived tests are performed
If additional space is needed, check here \Box and attach additional information using the same format.
VII. PPM TESTING If only applying for a Certificate for PPM, complete this section and skip section VIII (Non-Waived Testing).
Identify the PPM testing (to be) performed. Be as specific as possible. e.g. (Potassium Hydroxide (KOH) Preps, Urine Sediment Examinations)
Indicate the ESTIMATED TOTAL ANNUAL TEST volume for all PPM tests performed
If also performing waived complexity tests, complete Section VI. For laboratories applying for certificate of compliance or certificate of accreditation, also include PPM test volume in the specialty/subspecialty category and the "total estimated annual test volume" in section VIII.
Check if no PPM tests are performed
If additional space is needed, check here \square and attach additional information using the same format.

if you are applying for a Certificate of Compliance or a Certificate of Accreditation.

Identify the non-waived testing (to be) performed. Be as specific as possible. This includes each analyte test system or device used in the laboratory e.g. (Potassium, Acme Chemistry Analyzer).

VIII. NON-WAIVED TESTING (Including PPM testing if applying for a Certificate of Compliance or Accreditation) Complete this section only

If you perform testing other than or in addition to waived tests, complete the information below. If applying for one certificate for multiple sites, the total volume should include testing for ALL sites.

If additional space is needed, check here \square and attach additional information using the same format.

Place a check (🗸) in the box preceding each specialty/subspecialty in which the laboratory performs testing. Enter the estimated annual test volume for each specialty. Do not include testing not subject to CLIA, waived tests, or tests run for quality control, calculations, quality assurance or proficiency testing when calculating test volume. (For additional guidance on counting test volume, see the instructions included with the application package.)

If applying for a Certificate of Accreditation, indicate the name of the Accreditation Organization beside the applicable specialty/ subspecialty for which you are accredited for CLIA compliance. (The Joint Commission, AOA, AABB, A2LA, CAP, COLA or ASHI)

SPECIALTY / SUBSPECIALTY	ACCREDITING ORGANIZATION	ANNUAL TEST VOLUME	SPECIALTY / SUBSPECIALTY	ACCREDITING ORGANIZATION	ANNUAL TEST VOLUME
HISTOCOMPATIBILITY 010			HEMATOLOGY 400		
Transplant			Hematology		
Nontransplant			IMMUNOHEMATOLOGY		
MICROBIOLOGY			☐ ABO Group & Rh Group 510		
Bacteriology 110			Antibody Detection (transfusion) 520		
Mycobacteriology 115			Antibody Detection (nontransfusion) 530		
Mycology 120			Antibody Identification 540		
Parasitology 130			☐ Compatibility Testing 550		
☐ Virology 140			PATHOLOGY		
DIAGNOSTIC IMMUNOLOGY			Histopathology 610		
Syphilis Serology 210			Oral Pathology 620		
General Immunology 220			Cytology 630		
CHEMISTRY			RADIOBIOASSAY 800		
Routine 310			Radiobioassay		
Urinalysis 320			CLINICAL CYTOGENETICS 900		
Endocrinology 330			☐ Clinical Cytogenetics		
Toxicology 340 TOTAL ESTIMATED ANNUAL TEST VOLUME:					

IX. TYPE OF CONTROL (check the on	e most descriptive of ownersh	ip type)		
VOLUNTARY NONPROFIT	FOR PROFIT	GOVERNMENT		
□ 01 Religious Affiliation	☐ 04 Proprietary	□ 05 City		
□ 02 Private Nonprofit		☐ 06 County		
□ 03 Other Nonprofit		□ 07 State		
		□ 08 Federal		
(Specify)		□ 09 Other Gov	vernment	
			(Specify)	
X. DIRECTOR AFFILIATION WITH OTH	JED I ADODATODIES		(0,000)	
If the director of this laboratory service complete the following:	es as director for additional la	boratories that are separate	ely certified, please	
CLIA NUMBER	CLIA NUMBER NAME OF LABORATORY			
ATTENTION BEAD	THE FOLLOWING CAREFULLY	DEFORE CICAUNG ARRUGATIO	NI.	
ATTENTION: READ	THE FOLLOWING CAREFULLY E	BEFORE SIGNING APPLICATION	DN	
Any person who intentionally violate or any regulation promulgated there 18, United States Code or both, exceprequirement such person shall be imp United States Code or both.	under shall be imprisoned for ot that if the conviction is for a prisoned for not more than 3 y	not more than 1 year or fine a second or subsequent viola ears or fined in accordance	ed under title ation of such a with title 18,	
Consent: The applicant hereby agrees applicable standards found necessary section 353 of the Public Health Serviany Federal officer or employee duly its pertinent records at any reasonab determine the laboratory's eligibility requirements.	by the Secretary of Health and ce Act as amended. The applic designated by the Secretary, t le time and to furnish any requ or continued eligibility for its	d Human Services to carry or cant further agrees to permi- to inspect the laboratory and duested information or mater	ut the purposes of t the Secretary, or d its operations and ials necessary to	
PRINT NAME OF OWNER/DIRECTOR OF LABOR	RATORY			
SIGNATURE OF OWNER/DIRECTOR OF LABORA	ATORY (Sign in ink)		DATE	
NOTE: Completed 116 applications m completed 116 application.	ust be sent to your local State	Agency. Do not send any p	payment with your	

STATE AGENCY CONTACT INFORMATION CAN BE FOUND AT:

http://www.cms.gov/Regulations- and - Guidance/Legislation/CLIA/Downloads/CLIASA.pdf

THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA) APPLICATION (FORM CMS-116)

INSTRUCTIONS FOR COMPLETION

CLIA requires every facility that tests human specimens for the purpose of providing information for the diagnosis, prevention or treatment of any disease or impairment of, or the assessment of the health of, a human being to meet certain Federal requirements. If your facility performs tests for these purposes, it is considered, under the law, to be a laboratory. Facilities only collecting or preparing specimens (or both) or only serving as a mailing service are not considered laboratories. CLIA does not apply to a facility that only performs forensic testing. CLIA applies even if only one or a few basic tests are performed, and even if you are not charging for testing. In addition the CLIA legislation requires financing of all regulatory costs through fees assessed to affected facilities.

The CLIA application (Form CMS-116) collects information about your laboratory's operation which is necessary to determine the fees to be assessed, to establish baseline data and to fulfill the statutory requirements for CLIA. This information will also provide an overview of your facility's laboratory operation. All information submitted should be based on your facility's laboratory operation as of the date of form completion.

NOTE: WAIVED TESTS ARE NOT EXEMPT FROM CLIA. FACILITIES PERFORMING ONLY THOSE TESTS CATEGORIZED AS WAIVED MUST APPLY FOR A CLIA CERTIFICATE OF WAIVER.

NOTE: Laboratory directors performing non-waived testing (including PPM) must meet specific education, training and experience under subpart M (42 CFR PART 493) of the CLIA requirements. Proof of these requirements for the laboratory director must be submitted with the application. Information to be submitted with the application include:

- Verification of State Licensure, as applicable
- Documentation of qualifications:
 - Education (copy of Diploma, transcript from accredited institution, CMEs),
 - · Credentials, and
 - Laboratory experience.

Individuals who attended foreign schools must have an evaluation of their credentials determining equivalency of their education to education obtained in the United States. Failure to submit this information will delay the processing of your application.

ALL APPLICABLE SECTIONS MUST BE COMPLETED. INCOMPLETE APPLICATIONS CANNOT BE PROCESSED AND WILL BE RETURNED TO THE FACILITY. PRINT LEGIBLY OR TYPE INFORMATION.

I. GENERAL INFORMATION

For an initial applicant, check "initial application". For an initial survey or for a recertification, check "survey". For a request to change the type of certificate, check "change in certificate type" and provide the effective date of the change. For all other changes, including change in location, director, lab closure, etc., check "other changes" and provide the effective date of the change.

CLIA Identification Number: For an initial applicant, the CLIA number should be left blank. The number will be assigned when the application is processed. For all other applicants, enter the 10 digit CLIA identification number already assigned and listed on your CLIA certificate.

Facility Name: Be specific when indicating the name of your facility, particularly when it is a component of a larger entity, e.g., respiratory therapy department in XYZ Hospital. For a physician's office, this may be the name of the physician. NOTE: the information provided is what will appear on your certificate.

Physical Facility Address: This address is mandatory and must reflect the physical location where the laboratory testing is performed. The address may include a floor, suite and/or room location, but cannot be a Post Office box or Mail Stop.

If the laboratory has a separate mailing and/or corporate address (from the Facility Address), please complete the appropriate sections on the form.

Mailing Address: This address is optional and may be used if the laboratory wants to direct the mailing of the CLIA fee coupon and/or CLIA certificate to an alternate location, such as an accounts payable office. A Post Office box number or Mail Stop number may be used as part of the Mailing Address for this section.

Corporate Address: This address is optional and may be used if the laboratory wants to direct the mailing of the CLIA fee coupon and/or CLIA certificate to another location, such as, the main headquarters or home office for the laboratory. A Post Office box number or Mail Stop number may be used as part of the Corporate Address for this section.

Form Mailing: Select the address (Physical, Mailing, Corporate) where the CLIA fee coupon and CLIA certificate are to be mailed.

For Office Use Only: The date received is the date the form is received by the state agency or CMS regional office for processing.

II. TYPE OF CERTIFICATE REQUESTED

Select your certificate type based on the highest level of test complexity performed by your laboratory. A laboratory performing non-waived tests can choose Certificate of Compliance or Certificate of Accreditation based on the agency you wish to survey your laboratory.

When completing this section, please remember that a facility holding a: **Certificate of Waiver** can only perform tests categorized as waived;*

 Certificate for Provider Performed Microscopy Procedures (PPM) can only perform tests categorized as PPM, or tests categorized as PPM and waived tests;*

- Certificate of Compliance can perform tests categorized as waived, PPM and moderate and/or high complexity tests provided the applicable CLIA quality standards are met following a CLIA survey; and
- Certificate of Accreditation can perform tests categorized as waived, PPM and moderate and/ or high complexity non-waived tests provided the laboratory is currently accredited by an approved accreditation organization. (If your CMS-approved accreditation organization is not listed, contact your local State Agency for further instructions.)
- *A current list of waived and PPM tests may be obtained from your State agency. Specific test system categorizations can also be found on the Internet at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCLIA/clia.cfm.

III. TYPE OF LABORATORY

Select the type that is most descriptive of the location where the laboratory testing is performed.

If selecting 'mobile laboratory' (code 19), a mobile laboratory is defined as a movable, self-contained operational laboratory with its own personnel, equipment, and records. For record keeping purposes, include, on a separate sheet of paper, the vehicle identification numbers (VINs) of all vehicles used for mobile laboratory testing.

If selecting 'Practitioner Other' (code 22), this type includes practitioners such as, dentists, chiropractors, etc.

IV. HOURS OF ROUTINE OPERATION

Provide only the times when actual laboratory testing is performed in your facility. Please use the HH:MM format and check box marked '24/7' if laboratory testing is performed continuously, e.g., 24 hours a day, 7 days a week. Do not use military time.

V. MULTIPLE SITES

You can only qualify for the multiple site provision (more than one site under one certificate) if you meet one of the CLIA requirements described in 42 CFR 493. 493.35(b)(1-3), 493.43(b)(1-3) and 493.55(b)(1-3) Hospice and HHA could qualify for an exception.

VI. WAIVED TESTING

Indicate the estimated total annual test volume for all waived tests performed. List can be found at: http://www.cms.gov/CLIA/downloads/waivetbl.pdf

VII. PPM TESTING

Indicate the estimated total annual test volume for all PPM tests performed. List can be found at: https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/ppmplist.pdf

VIII. NON-WAIVED TESTING (INCLUDING PPM)

The total Estimated Annual Test volume in this section includes all non-waived testing, including PPM tests previously counted in section VII. Follow the specific instructions on page 3 of the Form CMS-116 when completing this section for test counting information. (Note: The Accrediting Organization column should reflect accreditation information for CLIA purposes only; e.g., CAP, etc.).

IX. TYPE OF CONTROL

Select the type of ownership or control which most appropriately describes your facility.

X. DIRECTOR OF ADDITIONAL LABORATORIES

List all other facilities for which the director is responsible and that are under different certificates. Note that for a Certificate of PPM, Certificate of Compliance or Certificate of Accreditation, an individual can only serve as the director for no more than five certificates.

Reminders - Before submitting the Form CMS-116:

- 1. Include the current or estimated annual test volume.
- 2. For Certificate for PPM, Certificate of Compliance, or Certificate of Accreditation, include the laboratory director qualifications.
- 3. Do not send any money with your application.
- 4. Send the completed Form CMS-116 to the appropriate State Agency (http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/CLIASA.pdf).

Once the completed Form CMS-116 has been returned to the applicable State agency and it is processed, a fee remittance coupon will be issued. The fee remittance coupon will indicate your CLIA identification number and the amount due for the certificate, and if applicable the compliance (survey) or validation fee. If you are applying for a Certificate of Compliance or Certificate of Accreditation, you will initially pay for and receive a Registration Certificate. A Registration Certificate permits a facility requesting a Certificate of Compliance to perform testing until an onsite inspection is conducted to determine program compliance; or for a facility applying for a Certificate of Accreditation, until verification of accreditation by an approved accreditation organization is received by CMS.

If you need additional information concerning CLIA, or if you have questions about completion of this form, please contact your State agency. State agency contact information can be found at:

http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/CLIASA.pdf

TESTS COMMONLY PERFORMED AND THEIR CORRESPONDING LABORATORY SPECIALTIES/SUBSPECIALITIES

HISTOCOMPATIBILITY (010)

HLA Typing (disease associated antigens)

MICROBIOLOGY

Bacteriology (110)

Gram Stain Culture Susceptibility

Strep screen

Antigen assays (H.pylori, Chlamydia, etc.)

Mycobacteriology (115)

Acid Fast Smear Mycobacterial culture Mycobacterial susceptibility

Mycology (120)

Fungal Culture

DTM

KOH Preps

Parasitology (130)

Direct Preps

Ova and Parasite Preps

Wet Preps

Virology (140)

RSV (Not including waived kits)

HPV assay Cell culture

DIAGNOSTIC IMMUNOLOGY

Syphilis Serology (210)

RPR

FTA, MHATP

General Immunology (220)

Allergen testing

ANA

Antistreptolysin O

Antigen/Antibody (hepatitis, herpes, rubella, etc.)

Complement (C3, C4)

Immunoglobulin

HIV

Mononucleosis assay

Rheumatoid factor

Tumor marker (AFP, CA 19-9, CA 15-3, CA 125)*

*Tumor markers can alternatively be listed under

Routine Chemistry instead of General Immunology.

HEMATOLOGY (400)

Complete Blood Count (CBC)

WBC count

RBC count

Hemoglobin

Hematocrit (Not including spun micro)

Platelet count

Differential

Activated Clotting Time

Prothrombin time (Not including waived instruments)

Partial thromboplastin time

Fibrinogen

Reticulocyte count

Manual WBC by hemocytometer
Manual platelet by hemocytometer
Manual RBC by hemocytometer

Sperm count

IMMUNOHEMATOLOGY

ABO group (510)

Rh(D) type (510)

Antibody screening

Antibody identification (540)

Compatibility testing (550)

PATHOLOGY

Dermatopathology

Oral Pathology (620)

PAP smear interpretations (630)

Other Cytology tests (630)

Histopathology (610)

RADIOBIOASSAY (800)

Red cell volume

Schilling test

CLINICAL CYTOGENETICS (900)

Fragile X

Buccal smear

Prader-Willi syndrome

FISH studies for: neoplastic disorders, congenital disorders or solid tumors.

CHEMISTRY

Routine Chemistry (310)

Albumin Ammonia Alk Phos ALT/SGPT AST/SGOT Amylase Bilirubin

Blood gas (pH, pO2, pCO2)

BUN
Calcium
Chloride
Cholesterol
Cholesterol, HDL
CK/CK isoenzymes

CO2 Creatinine Ferritin Folate GGT

Glucose (Not fingerstick)

Iron

LDH/LDH isoenzymes

Magnesium Potassium

Protein, electrophoresis

Protein, total

PSA Sodium Triglycerides Troponin Uric acid Vitamin B12

Endocrinology (330)

Cortisol

HCG (serum pregnancy test)

T3

T3 Uptake

T4

T4, free

TSH

Toxicology (340)

Acetaminophen Blood alcohol

Blood lead (Not waived)

Carbamazepine

Digoxin
Ethosuximide
Gentamicin
Lithium

Phenobarbital
Phenytoin
Primidone
Procainamide
NAPA
Quinidine
Salicylates
Theophylline
Tobramycin

Therapeutic Drug Monitoring

Urinalysis** (320)

Automated Urinalysis (Not including waived instruments)

Microscopic Urinalysis

Urine specific gravity by refractometer Urine specific gravity by urinometer Urine protein by sulfosalicylic acid

** Dipstick urinalysis is counted in Section VI. WAIVED TESTING

NOTE: This is not a complete list of tests covered by CLIA. Other non-waived tests and their specialties/ subspecialties can be found at http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/SubjecttoCLIA.pdf and http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/CLIASA.pdf.

http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/CLIASA.pdf.

GUIDELINES FOR COUNTING TESTS FOR CLIA

- For **histocompatibility**, each HLA typing (including disease associated antigens), HLA antibody screen, or HLA crossmatch is counted as one test.
- For microbiology, susceptibility testing is counted as one test per group of antibiotics used to determine sensitivity for one organism. Cultures are counted as one per specimen regardless of the extent of identification, number of organisms isolated and number of tests/procedures required for identification.
- For general immunology, testing for allergens should be counted as one test per individual allergen.
- For hematology, each measured individual analyte of a complete blood count or flow cytometry test that is
 ordered and reported is counted separately. The WBC differential is counted as one test.
- For **immunohematology**, each ABO, Rh, antibody screen, crossmatch or antibody identification is counted as one test.
- For histopathology, each block (not slide) is counted as one test. Autopsy services are not included. For
 those laboratories that perform special stains on histology slides, the test volume is determined by adding
 the number of special stains performed on slides to the total number of specimen blocks prepared by
 the laboratory.
- For cytology, each slide (not case) is counted as one test for both Pap smears and nongynecologic cytology.
- For clinical cytogenetics, the number of tests is determined by the number of specimen types processed on each patient; e.g., a bone marrow and a venous blood specimen received on one patient is counted as two tests.
- For chemistry, each analyte in a profile counts as one test.
- For **urinalysis**, microscopic and macroscopic examinations, each count as one test. Macroscopics (dipsticks) are counted as one test regardless of the number of reagent pads on the strip.
- For all specialties/subspecialities, do not count calculations (e.g., A/G ratior, MCH, T7, etc.), quality control, quality assurance, or proficiency testing assays.

If you need additional information concerning counting tests for CLIA, please contact your State agency.





CalREDIE Manual Laboratory Reporting Module (MLRM) Reporting Antigen Test Results September 2020

Per Title 17 section 2505 of the California Code of Regulations, any entity performing SARS-CoV-2 testing is required to report both positive and non-positive results to public health. Results must be reported to the local health department where the patient resides within eight (8) hours. These laboratory test data are critical for public health disease control and response activities.

Entities performing SARS-CoV-2 point-of-care tests (POC), including PCR and antigen tests are required to report ALL test results. This includes, but is not limited to, the Quidel Sofia SARS Antigen FIA and BD Veritor System.

The CalREDIE Manual Lab Reporting Module (MLRM) can be used to meet these reporting requirements. CalREDIE is the state wide reportable condition reporting system. MLRM allows users to report results for each patient tested directly to the local health department where the patient resides. Entities in San Diego or Los Angeles Counties should not use MLRM and should contact their local health department for instructions on how to report.

Steps to Report via CalREDIE MLRM:

- 1. Complete the CalREDIE <u>Manual Lab Reporting Account Request Form</u>. Each person who will be reporting results must complete this form.
- 2. Submit completed account form to calrediehelp@cdph.ca.gov.
- 3. CalREDIE Helpdesk will process the account and send the user his/her login credentials.
- 4. Review the CalREDIE <u>Manual Lab Reporting Quick Start Guide</u>. This Guide walks the user through how to log in and submit a result in the MLRM.
- 5. Login to the CalREDIE MLRM and begin submitting results.
- 6. Contact calrediehelp@cdph.ca.gov with any questions.








Getting Started (Figure 1)

- *CalREDIE is only compatible with Internet Explorer.
- *Do not enter HIV/AIDS information in CalREDIE.
 - 1. Enter https://calredie.cdph.ca.gov in your Internet Explorer address bar and press enter.
 - 2. Enter your CalREDIE username and password.
 - 3. Click Login.
 - 4. Use the fields at the top of the Manual Lab Report page to search for previously submitted results.
 - 5. Click **New Lab Report** and scroll down to report a new result.

Figure 1



Submitting a Manual Lab Report: Patient Demographics (Figure 2)

- *ALL of the demographic information listed in #1 through #5 below must be completed. Other demographic information is optional.
 - 1. Enter Last Name and First Name.
 - 2. Enter Date of Birth and Age will auto-calculate
 - 3. Enter Address, City, State, and Zip Code.
 - 4. Enter Home Telephone number.
 - 5. Enter **Gender**, **Ethnicity**, and **Race**.

Figure 2








CalREDIE Manual Lab Reporting Quick Start Guide

Result Details (Figure 3):

*The four fields described in #1 through #4 below must be completed. All other fields are optional.

- 1. Enter Result Name.
 - a. Click on the pop-up box to the right of the "Result Name" field to bring up the LOINC Dictionary.
 - b. Search for the LOINC Code being reported and select the blue hyperlinked LOINC Name. This will highlight your selection in yellow.
 - c. Click "OK." The "Result Name" field is now populated.
 - d. Note: To clear this field, hit the "Clear selection" button, with the "X" through it.
- 2. Select 'Positive' or 'Negative'.
- 3. Enter **Value**. Acceptable values are: Detected, Not Detected, Inconclusive, Specimen Unsatisfactory.
- 4. Enter **Confirm Value** (Value must be re-entered here).
- 5. To enter a Note, click Add Note button.
- 6. To add another result, for the same patient, click the **Add** button.

Figure 3








CalREDIE Manual Lab Reporting Quick Start Guide

Specimen Details and Submitting Results (Figure 4):

- 1. Enter the Accession Number.
- 2. Enter Ordering Physician and Provider Identifier, if known.
- 3. Enter dates for Specimen Collected, Specimen Received, and Specimen Resulted.
 - a. Use the calendar icon to select a date or enter the date manually.
- 4. Leave Specimen Type, Result, and Specimen Collection Notes blank.
- 5. Click **Save** when finished. When the Save button is clicked, the result is submitted to CalREDIE.

Figure 4



Questions? Contact the CalREDIE Help Desk: CalREDIEHelp@cdph.ca.gov